Bio Essence Corp
BIOEdata completeness 75%6 fiscal years on fileData notes: no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'dividendsPaid'
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $887,9841 | $621,5902 | $551,5062 | $323,9403 | $1.9M3 |
| Net income | −$647,5644 | −$809,6795 | −$971,8796 | −$1.31M7 | $896,1977 |
| Operating cash flow | −$1.29M8 | −$703,2419 | −$1.03M10 | $623,86511 | $1.57M11 |
| Capital expenditure | $119,49612 | $3,74213 | $3,61414 | — | — |
| Free cash flow (derived) | −$1.41M8 | −$706,9839 | −$1.03M10 | — | — |
| Total debt | — | — | — | $56,48115 | $57,48216 |
| Cash & equivalents | $30317 | $6,26218 | $11418 | $1,37119 | — |
| Diluted shares | 33.0M | 33.0M | 36.0M | 38.0M | 38.0M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$0.55 of net worth that earned you $0.24 last year, against $0.02 of debt.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is up 15% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001213900-23-024571 (Revenues)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032898 (RevenueFromContractWithCustomerIncludingAssessedTax)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-035467 (Revenues)
- 10-K · period ending 2021-12-31 · accession 0001213900-23-024571 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032898 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001013762-25-003850 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-035467 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001213900-23-024571 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032898 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001013762-25-003850 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001213900-26-035467 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001213900-22-016613 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032898 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001013762-25-003850 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001013762-25-003850 (LongTermDebt)
- 10-K · period ending 2025-12-31 · accession 0001213900-26-035467 (LongTermDebt)
- 10-K · period ending 2021-12-31 · accession 0001213900-23-024571 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001213900-24-032898 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001013762-25-003850 (CashAndCashEquivalentsAtCarryingValue)